Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Suspended · Phase 2 · NCT06575686
Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
At a glance
- Research payments reported, 2025
- $689,381
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 33
About the trial
- Sponsor
- City of Hope Medical Center (with National Cancer Institute (NCI))
- Tested
- Biospecimen Collection (procedure), Bone Marrow Biopsy (procedure), Computed Tomography (procedure), Epcoritamab (biological), Positron Emission Tomography (procedure), Tazemetostat (drug)
- Dates
- Started 2025-03-11; completion 2028-07-16
- Results posted
- Not yet
This phase II trial tests the safety, side effects and effectiveness of epcoritamab and tazemetostat in treating patients with grade I-IIIa follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab is a bispecific monoclonal antibody that binds to two different antigens on the surface of cancer cells that may help the body's immune system attack the cancer and may interfere with the ability of the cancer cells to grow and spread. Tazemetostat, a EZH2 inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving epcoritamab and tazemetostat may be …
From ClinicalTrials.gov, last updated 2026-01-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $689,381 in research payments for this study in 2025 (2 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $689,381
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.